Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
CRANBURY, N.J., Dec. 21, 2017 -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 9, 2018 at 8:00am PT.
An audio webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
CONTACTS:
Investors/Media:
Amicus Therapeutics
Sara Pellegrino, IRC
Senior Director, Investor Relations
[email protected]
(609) 662-5044
Media:
Pure Communications
Jennifer Paganelli
[email protected]
(347) 658-8290
FOLD–G
